Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2852W HIGH $17.25
Volume
18.57 K
Value Traded
6.97 M
Short % Float
15.79%
-6.89%Week
-23.5%1 Month
-24.36%3 Month
-5.51%6 Month
-59.05%5 Year
-60.82%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
720.94 M
EPS (TTM)
-1.13
P/E Ratio
-
Ent. Value
511.67 M
Total Shares
62.55 M
Float Shares
34.58 M
Insiders
44.74%
Institutions
60.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DSGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Design Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Design Therapeutics, Inc.
122Total events
6Upcoming
23Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Protocol AmendmentDT-216P2Trial
Modifications to RESTORE-FA trial announced
Friedreich ataxiasource ↗
▲First Patient DosedDT-818Trial
Patient dosing initiated in Phase 1 MAD trial of DT-818
myotonic dystrophy type 1source ↗
◆Topline ReadoutDT-216P2Clinical Data
Update on effect of DT-216P2 on endogenous frataxin levels after 12 weeks of dosing
Friedreich Ataxia (FA)source ↗
◆Topline ReadoutDT-168Clinical Data
Data from Phase 2 biomarker trial of DT-168 in FECD
Fuchs Endothelial Corneal Dystrophy (FECD)source ↗
▲First Patient DosedDT-818Trial
Initiation of patient dosing in Phase 1 MAD trial of DT-818 for DM1
myotonic dystrophy type-1source ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
◆Oral PresentationDT-216P2Presentation
Investor webcast to review data from RESTORE-FA trial of DT-216P2
Friedreich's ataxiasource ↗
▲Topline ReadoutDT-216P2Clinical Data
Positive four-week data from RESTORE-FA reported in May 2026
Friedreich ataxiasource ↗
◆First Patient DosedDT-818Trial
First patient dosed in Phase 1 MAD trial of DT-818 in DM1
Myotonic Dystrophy Type-1 (DM1)source ↗
▲Other Regulator MilestoneDT-818Ex-US Regulatory
Obtained ex-US regulatory clearance for DT-818
Myotonic Dystrophy Type-1 (DM1)source ↗
▲First Patient DosedDT-216P2Trial
RESTORE-FA Phase 1/2 multiple-ascending dose trial of DT-216P2 in FA patients underway
Friedreich Ataxiasource ↗
▲Trial InitiationDT-168Trial
Phase 2 biomarker study for DT-168 initiated in patients with FECD
Fuchs Endothelial Corneal Dystrophysource ↗
▲PK PD DataDT-216P2Clinical Data
Early human pharmacokinetics data for DT-216P2 demonstrates favorable translation from NHPs to humans
Friedreich Ataxiasource ↗
◆Trial InitiationDT-168Trial
Initiation of Phase 2 biomarker trial
Fuchs endothelial corneal dystrophysource ↗
◆Oral PresentationPresentation
Management presentation at 2025 Jefferies Global Healthcare Conference
▲First Patient DosedDT-216P2Trial
First FA patient dosed in MAD trial ex-U.S.
Friedreich ataxiasource ↗
▼Clinical Hold PlacedDT-216P2IND
FDA placed clinical hold on IND for U.S. sites
Friedreich ataxiasource ↗
◆Trial InitiationDT-216P2Trial
Initiation of DT-216P2 MAD patient study expected mid-2025
Friedreich Ataxiasource ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at 2025 RBC Capital Markets Healthcare Conference
▲First Patient DosedDT-216P2Trial
Phase 1 SAD trial of DT-216P2 ongoing in healthy volunteers
Friedreich Ataxiasource ↗
◆Oral PresentationDT-168Presentation
Presentation of Phase 1 safety data and Phase 2 plans for DT-168 at Eyecelerator @ Park City 2025
Fuchs endothelial corneal dystrophy (FECD)source ↗
▲Full ResultsDT-168Clinical Data
Favorable Phase 1 data for DT-168 reported at Eyecelerator @ Park City 2025
Fuchs Endothelial Corneal Dystrophysource ↗
●Oral PresentationDT-168Presentation
Presentation of Phase 1 DT-168 data at Eyecelerator @ Park City 2025
Fuchs Endothelial Corneal Dystrophysource ↗
◆Trial InitiationDT-216P2Trial
Phase 1/2 MAD trial in FA patients anticipated to begin in mid-2025
Friedreich Ataxiasource ↗
▲First Patient DosedDT-216P2Trial
Initiated Phase 1 SAD trial of DT-216P2 in healthy volunteers
Friedreich Ataxiasource ↗
▲Enrollment CompleteDT-168Trial
Completed dosing in Phase 1 MAD trial of DT-168 in healthy volunteers
Fuchs Endothelial Corneal Dystrophysource ↗
▲Enrollment MilestoneTrial
Enrollment target achieved in FECD observational study (approx. 250 patients)
Fuchs Endothelial Corneal Dystrophysource ↗
▲First Patient DosedDT-216P2Trial
FA patient dosing expected to begin later in 2025
Friedreich Ataxia (FA)source ↗
◆Trial InitiationDT-216P2Trial
Start patient trials for DT-216P2 in 2025
Friedreich Ataxia (FA)source ↗
◆Development Candidate NominationPreclinical
Selection of development candidate for DM1 program expected later in 2025
Myotonic Dystrophy Type-1source ↗
◆Topline ReadoutDT-216Clinical Data
Initial data expected from multiple-dose Phase 1 trial with improved formulation
Friedreich Ataxiasource ↗
▲Trial InitiationDT-168Trial
Phase 1 trial initiated for DT-168 in FECD
Fuchs Endothelial Corneal Dystrophy (FECD)source ↗
●Enrollment UpdateDT-168Trial
Observational study currently enrolling patients
Fuchs Endothelial Corneal Dystrophysource ↗
Past FDA Catalysts and PDUFA Decisions
How DSGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | DT-168 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$39M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Design Therapeutics, Inc. faces pipeline headwinds (33/100), with $97M risk-adjusted pipeline value, led by DT-168 in Fuchs Endothelial Corneal Dystrophy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT-168 Small moleculeNCT07024693 | Fuchs Endothelial Corneal Dystrophy | Phase 2 | RECRUITING | 70 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every DSGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DT-216P2 | Friedreich Ataxia | Phase 1/2 | 2025-08-07 | Early human PK data for DT-216P2 demonstrate the consistency of human plasma exposure profiles with NHP data across both IV and subcutaneous routes.Read More | Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shapiro DavidDirector | Grant/Award | 60,000 60,000 held | $0.00 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DSGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Logos Global Management LP | 1.9 % (90 %) | 43.41 M | 3.00 M | 53.85% ( 1.05 M) |
DSGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DSGN ranks across every disease it competes in
Competitive Position is a premium feature
See how DSGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDSGN News
DSGNDesign Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Design Therapeutics, a clinical-stage biotechnology company, will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference on September 9, 2026. The event includes a fireside chat at 2:45 p.m. ET in New York, which will be available via live webcast. The company focuses on developing GeneTAC® therapies for serious degenerative genetic diseases.
Read more →DSGNDesign Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics provided an update on its RESTORE-FA trial, highlighting positive four-week data for DT-216P2 and modifications to support further development. The company also initiated a Phase 1 trial for DT-818 in myotonic dystrophy type 1. Financial results showed a strong cash position of $207.4 million, despite a net loss of $20.2 million.
Read more →DSGNDesign Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has commenced patient dosing in a Phase 1 trial for DT-818, aimed at treating myotonic dystrophy type-1 (DM1). This trial will evaluate the safety and pharmacokinetics of the drug, which targets the mutant DMPK allele responsible for DM1. The company anticipates reporting results in 2027, marking a crucial step in addressing this genetic disorder.
Read more →DSGNDesign Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will showcase the company's innovative GeneTAC platform, which targets genetic diseases. A live webcast will be available, and the session will be archived for 30 days. This participation underscores the company's focus on advancing its clinical-stage programs.
Read more →DSGN▼ -25.5%on this news
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
Design Therapeutics announced positive results from the Phase 1/2 RESTORE-FA trial of DT-216P2, showing significant clinical improvements in Friedreich ataxia patients after four weeks of treatment. The therapy demonstrated dose-dependent increases in frataxin levels and was well-tolerated. The company plans to advance DT-216P2 toward registrational development based on these findings.
Read more →DSGN▼ -25.5%on this news
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics will present data from its Phase 1/2 RESTORE-FA trial of DT-216P2 for Friedreich's ataxia on May 18, 2026. The company is focused on developing therapies for serious genetic diseases using its GeneTAC platform. The webcast will be accessible to investors and archived for later viewing.
Read more →DSGN▲ +23.3%on this news
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Design Therapeutics announced its first quarter 2026 financial results, highlighting a cash position of $222.8 million and ongoing clinical trials, particularly the RESTORE-FA trial for DT-216P2 aimed at treating Friedreich ataxia. The company also appointed Dr. David Shapiro to its Board of Directors to strengthen its clinical and regulatory capabilities. Despite positive developments, the company acknowledged potential risks associated with clinical trials.
Read more →DSGNDesign Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
Design Therapeutics reported its fourth-quarter and full-year financial results for 2025, highlighting ongoing clinical trials for its GeneTAC portfolio, including DT-216P2, DT-168, and DT-818. The company has a robust cash position of $219.8 million, which supports its operations through at least 2029. Anticipated data readouts from these trials are expected in the second half of 2026, reflecting significant progress in their clinical development. However, Design faces challenges such as a substantial net loss and dependencies on upcoming clinical results.
Read more →DSGNDesign Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, a clinical-stage biotechnology company, has announced its participation in upcoming investor conferences. The company focuses on developing GeneTAC therapies for serious degenerative genetic diseases, including Friedreich ataxia and myotonic dystrophy type-1. Live webcasts of the presentations will be available on their website, archived for 30 days.
Read more →DSGNDesign Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Design Therapeutics announced plans to initiate patient dosing of DT-818 for Myotonic Dystrophy Type-1 (DM1) in the first half of 2026. The company reported strong financial results for Q3 2025, with $206 million in cash to support its pipeline. DT-818 is positioned as a potentially best-in-disease treatment, while trials for other candidates continue to progress.
Read more →DSGNDesign Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics has appointed Justin Gover to its Board of Directors, effective immediately. Gover brings over 25 years of biotechnology experience, notably as the founding CEO of GW Pharmaceuticals. This transition follows the departure of Dr. Arsani William, who played a crucial role in the company's growth. Gover's expertise is expected to support the advancement of Design's clinical pipeline.
Read more →DSGNDesign Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics, Inc. will participate in the 2025 Cantor Global Healthcare Conference on September 4, 2025. The event will feature a fireside chat with management, which will be available via live webcast. The company is focused on developing GeneTAC therapies for serious genetic diseases, including Friedreich ataxia and Fuchs endothelial corneal dystrophy.
Read more →DSGN▲ +7.8%on this news· ran to +37% by day 3
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Design Therapeutics reported significant advancements in its GeneTAC® programs, highlighting early human pharmacokinetics data for DT-216P2 and the initiation of a Phase 2 biomarker study for DT-168. The company maintains a strong financial position with $216.3 million in cash and securities to support ongoing development. However, potential FDA clinical holds could impact timelines for U.S. trials.
Read more →DSGNDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Design Therapeutics has initiated dosing of the first patient in its RESTORE-FA Phase 1/2 trial for Friedreich ataxia with DT-216P2. Initial data from a prior trial indicates a favorable safety profile. However, the company faces a clinical hold from the FDA on its IND application for U.S. sites due to nonclinical deficiencies. The trial is currently open for enrollment in Australia, with data expected in 2026.
Read more →DSGNDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics, a clinical-stage biotechnology company, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025. The presentation will focus on their innovative GeneTAC platform, which aims to treat serious degenerative genetic diseases. The event will be available via live webcast and archived for later viewing.
Read more →DSGNDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
Design Therapeutics, a clinical-stage biotech firm, will participate in the 2025 RBC Capital Markets Healthcare Conference on May 20, 2025. The event will feature a fireside chat with management at 8:00 a.m. ET in New York. The company focuses on developing GeneTAC therapies for genetic diseases, including Friedreich ataxia and Fuchs endothelial corneal dystrophy.
Read more →DSGN▼ -8.3%on this news
Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results
Design Therapeutics, a biotechnology firm focused on genetic diseases, announced progress in its GeneTAC programs alongside their financial results for Q1 2025. The company reported promising Phase 1 data for its therapy DT-168 targeting Fuchs endothelial corneal dystrophy (FECD) and is advancing plans for a Phase 2 trial. Additionally, they are conducting a Phase 1 clinical trial for DT-216P2 aimed at Friedreich Ataxia (FA). The company maintains a strong cash position to support its operations through multiple trial phases over the coming years.
Read more →DSGNDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
Design Therapeutics announced positive Phase 1 trial results for DT-168, an eye drop treatment targeting the mutant TCF4 gene linked to Fuchs endothelial corneal dystrophy (FECD). The company plans to initiate a Phase 2 biomarker trial later in 2025, aiming to evaluate safety and corneal endothelium biomarkers in FECD patients. This could lead to the first disease-modifying therapy for this condition.
Read more →DSGN▲ +10.3%on this news
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
Design Therapeutics will present Phase 1 data for its DT-168 program targeting Fuchs endothelial corneal dystrophy at Eyecelerator @ Park City 2025. The presentation will cover safety findings from trials in healthy volunteers and future plans for Phase 2 development. DT-168 aims to address the genetic cause of FECD, which currently lacks effective treatments.
Read more →About Design Therapeutics, Inc.
Headquarters6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, 92011
BIOPHARMAWATCH ELITE PLUS
Trade the next DSGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime